- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00255502
307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects
January 14, 2020 updated by: AstraZeneca
A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Open-Label Extension of Protocol 307A
This was a 52-week, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of TOPROL-XL (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects.
The study population included school age children (age 6 to 12 years < Tanner Stage 3) and adolescents (> 12 years old or > Tanner Stage 3 to 16 years old) of both genders.
Because response to some therapies in adult hypertension appears to be different in black and non-black populations, the recruitment will have a mixture of black and non-black subjects.
Pharmacokinetic measurements were performed on a subset of patients.
Thirty subjects (15 subjects each in the 6 to 12 year age group and the 13 to 16 year age group) had a series of blood samples drawn.
All subjects had a trough plasma level taken 24 hours after the last dose of open-label metoprolol CR/XL (Visit 18) with the exception of those subjects who completed Protocol 307B (16 week open-label treatment).
Study Overview
Study Type
Interventional
Enrollment
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Santa Domingo, Dominican Republic
- Research Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Research Site
-
-
California
-
Bellflower, California, United States
- Research Site
-
Beverly Hills, California, United States
- Research Site
-
Los Angeles, California, United States
- Research Site
-
Orange, California, United States
- Research Site
-
-
Connecticut
-
Hartford, Connecticut, United States
- Research Site
-
-
Delaware
-
Wilmington, Delaware, United States
- Research Site
-
-
Florida
-
Gainesville, Florida, United States
- Research Site
-
Miami, Florida, United States
- Research Site
-
Orlando, Florida, United States
- Research Site
-
Tampa, Florida, United States
- Research Site
-
-
Hawaii
-
Honolulu, Hawaii, United States
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, United States
- Research Site
-
-
New Jersey
-
Livingston, New Jersey, United States
- Research Site
-
-
New York
-
Bronx, New York, United States
- Research Site
-
New Hyde Park, New York, United States
- Research Site
-
-
North Carolina
-
Durham, North Carolina, United States
- Research Site
-
Winston-Salem, North Carolina, United States
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- Research Site
-
Cleveland, Ohio, United States
- Research Site
-
Columbus, Ohio, United States
- Research Site
-
-
Pennsylvania
-
Lansdale, Pennsylvania, United States
- Research Site
-
Philadelphia, Pennsylvania, United States
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, United States
- Research Site
-
-
Texas
-
Beaumont, Texas, United States
- Research Site
-
Houston, Texas, United States
- Research Site
-
San Antonio, Texas, United States
- Research Site
-
-
Utah
-
Salt Lake City, Utah, United States
- Research Site
-
-
Virginia
-
Norfolk, Virginia, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 16 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between the ages of 6 and 16 years inclusive at the time of screening.
- Have a negative urine pregnancy test, if female of childbearing potential. Have a signed informed consent by a parent or a legal guardian and an assent form signed by the subject (if applicable).
Have hypertension that is either:
- Have successfully completed Protocol 307A, or, or
- Have dropped out of Protocol 307A or failed screening for Protocol 307A for sitting SBP/DBP greater than 20/10 mm Hg over the 95 th percentile using height adjusted charts for age and gender (see Appendices B through E inclusive), or
- Have not enrolled in Protocol 307A but meet all screening criteria for Protocol 307B and are enrolled at sites that have already randomized 6 subjects into Protocol 307A.
- Have the ability to swallow tablets.
Exclusion Criteria:
- Have secondary hypertension due to coarctation of aorta, pheochromocytoma, hyperthyroidism or Cushing's syndrome.
- Have a heart rate < 55 beats per minute at Visit 1.
- Have a history of asthma and/or recurring pulmonary disease or infections.
- Have a history of cystic fibrosis.
- Have a known hypersensitivity reaction to beta-blockers.
- Have a known bleeding, coagulation or platelet disorder that can interfere with blood sampling.
- Have a history of Insulin Dependent Diabetes Mellitus.
- Be in any situation or have any condition which, in the opinion of the investigator or sponsor, may interfere with participation in the study or produce a significant risk to the subject or interfere with the assessment of safety and efficacy endpoints.
- Have received any investigational agent for any therapeutic reason within 30 days prior to receiving study medication.
- Have a clinically significant cardiac valvular disease.
- Have a diagnosis of heart failure.
- Have clinically significant arrhythmia. This is defined as any arrhythmia requiring medical therapy or that causes symptoms.
- Atrioventricular (AV) conduction disturbance, ie, second or third degree AV block.
- Be unable or unwilling to comply with the study requirements.
- Be non-compliant during the single-blind placebo run-in period of the study as defined by missing three or more doses between study visits.
- Have impaired liver function defined as either acute liver disease or chronic liver disease with persistent liver enzyme values greater than one and one half times the upper limit of the normal range for AST or ALT.
- Have a known history of bilateral renal artery stenosis, or unilateral renal artery stenosis to a single kidney. Nephrotic subjects who are not in remission should be excluded.
- Be pregnant or breast-feeding an infant.
- Currently taking medications known to inhibit CYP2D6, such as quinidine, fluoxetine, paroxetine and propafenone.
- Currently taking catecholamine-depleting medications such as reserpine. For any subject who is currently taking medications known to inhibit CYP2D6 or any catecholamine-depleting medication, the sponsor must be contacted to assess feasibility for inclusion into the study.
- Currently taking any selective serotonin re-uptake inhibitors (SSRIs) or atypical antipsychotic medication.
- Have a history of alcohol or drug abuse, or have a positive urine screen for drugs of abuse or alcohol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The purpose of this trial is to evaluate the pharmacokinetics and long term safety and
|
tolerability of metoprolol CR/XL in hypertensive pediatric subjects.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Study Registration Dates
First Submitted
November 17, 2005
First Submitted That Met QC Criteria
November 17, 2005
First Posted (ESTIMATE)
November 21, 2005
Study Record Updates
Last Update Posted (ACTUAL)
January 18, 2020
Last Update Submitted That Met QC Criteria
January 14, 2020
Last Verified
November 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
- D4020C00001
- 307B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on metoprolol succinate
-
SanionaCompleted
-
East Coast Institute for ResearchCompletedHypertension | Female Sexual DysfunctionUnited States
-
University of MinnesotaUniversity of Alabama at Birmingham; United States Department of DefenseTerminatedPulmonary Disease, Chronic ObstructiveUnited States
-
University of CincinnatiTerminated
-
Gilead SciencesAstraZenecaTerminatedEnoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart FailureHeart Failure, CongestiveUnited States
-
CytokineticsRecruitingObstructive Hypertrophic Cardiomyopathy (oHCM)United States, Denmark, Spain, Netherlands, United Kingdom, France, China, Israel, Italy, Germany, Hungary, Canada
-
Damanhour Teaching HospitalRecruitingHypotension Drug-InducedEgypt
-
University of MichiganCompletedHemodialysis | PharmacokineticsUnited States
-
Mayo ClinicAstraZenecaCompletedHeart Valve DiseasesUnited States
-
AstraZenecaCompletedHypertensionUnited States, Dominican Republic